HIGH POINT, N.C. --(BUSINESS WIRE)--May 12, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today provided a corporate update and reported
Data featured in an oral presentation show TTP273 is the first GLP-1R agonist without significant gastrointestinal side effects HIGH POINT, N.C. --(BUSINESS WIRE)--Apr. 20, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and
HIGH POINT, N.C. --(BUSINESS WIRE)--Apr. 12, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the Company has been selected
HIGH POINT, N.C. --(BUSINESS WIRE)--Apr. 6, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe , President
HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 4, 2016-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe , President
- Launched pivotal Phase 3 STEADFAST study with azeliragon in Alzheimer’s disease - Completed enrollment of AGATA Phase 2b study with liver-selective Glucokinase Activator in Type 2 diabetes, with expected data readout in mid-2016 - Initiated LOGRA Phase 2b study with oral GLP-1R agonist in Type 2
Data presented at Keystone Symposia on Molecular and Cellular Biology KEYSTONE, Colo. --(BUSINESS WIRE)--Feb. 22, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s
Oral Glucokinase Activator has potential to address an underlying cause of Type 2 diabetes Company expects to report topline results in mid-2016 HIGH POINT, N.C. --(BUSINESS WIRE)--Feb. 9, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the
HIGH POINT, N.C. --(BUSINESS WIRE)--Jan. 28, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe , President
TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential Topline results are expected at the end of 2016 HIGH POINT, N.C. --(BUSINESS WIRE)--Jan. 21, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development